Pulmoner hipertansiyonlu hastalarda comet analizi ile değerlendirilen artmış DNA hasarı

Abstract

Amaç: Pulmoner hipertansiyonda (PH) görülen patolojik lezyonlar, oksidatif stres ve inflamatuar süreçlerle karakterizedir. Çalışmamızın amacı, PH hastalarında DNA hasarının potansiyel katkısını araştırmaktır.

Gereç ve Yöntem: Çalışmamıza 28 tedavi almamış PH hastası (59.93 ± 11.19 yıl) ve 28 yaş-cinsiyet uyumlu (59.86 ± 11.92 yıl) sağlıklı kontrol dahil edilmiştir. Tüm hastalara tanıyı doğrulamak ve hemodinamiyi değerlendirmek için sağ kalp kateterizasyonu uygulanmıştır. Bireylerden alınan venöz kan örneklerinde, DNA hasarı belirlenmesinde tek hücre jel elektroforezi ve flüoresan mikroskopisine dayanan, onarımdan önce DNA hasarını tespit eden kuyruklu yıldız (Comet) analizi kullanılmıştır. Sürekli veriler ortalama ± standart sapma (SD) olarak verilmiş, normallik testi için Shapiro-Wilk testleri kullanılmıştır. Bağımsız gruplar için Mann Whitney U testi, kategorik değişkenler için ki-kare testi kullanılmıştır. İstatistiksel analizlerde SPSS, 24.0 programı kullanılmış ve p≤0.05 değerleri istatistiksel olarak anlamlı kabul edilmiştir.

Bulgular: Ortalama pulmoner vasküler direnç 5.64 ± 2.99 Wood Unitesi, ortalama sağ atriyal basınç 9.70 ± 5.38 mmHg, kardiyak indeks 3.12 ± 1.18 l / dak / m₂, mixed venöz O₂ saturasyonu % 64.77 ± 13.33 olarak saptanmıştır. DNA hasar parametrelerinden, kuyruk uzunluğu (24.02 ± 11.34 ve 16.88 ± 3.55 μm, p = 0.0001), kuyruk momenti (1.93 ± 2.36 ve 0.87 ± 1.03 μm, p = 0.013), kuyruk göçü (10.3 ± 12.24 ve 3.62  ± 2.75, p = 0.03) hastalarda istatistiksel olarak anlamlı düzeyde yüksek saptanmıştır.

Sonuç: Bulgularımız, PH hastalarında DNA tamir mekanizmaları devreye girmeden önce DNA hasarının artmış olabileceğini göstermektedir. DNA hasarı PH patofizyolojisine katkıda bulunabilir ve/veya PH'da yeni bir farmakolojik hedef olarak ele alınabilir.

Keywords

• Pulmoner hipertansiyon,DNA hasarı

Increased DNA damage with comet assay in patients with pulmonary hypertension

Abstract

Purpose: In pulmonary hypertension (PH), pathologic lesions are characterized by oxidative stress and inflammatory processes. The purpose of our study was to investigate the potential contribution of DNA damage in PH.

 

Materials and methods: The study comprised 28 treatment-naive PH patients (59.93±11.19 years) and 28 age- and sex-matched (59.86±11.92 years) healthy controls. All participants underwent a right-heart catheterization to confirm the diagnosis and to asses hemodynamics. Venous blood was obtained from participants. DNA damage were evaluated using the comet assay which is based on single cell gel electrophoresis and fluorescent microscopy and detects DNA damage prior to repair. Continuous data were reported as mean ± standard deviation (SD). Shapiro–Wilk tests were used for testing normality. Mann Whitney U test was used for independent groups. For categorical variables, Chi-square test was used. SPSS, 24.0 was used for statistical analyses and p value less than 0.05 was considered statistically significant.

 

Results: The average pulmonary vascular resistance was 5.64±2.99 WU, mean right atrial pressure was 9.70±5.38 mmHg, cardiac index was 3.12±1.18 l/min/m², mixed venous O₂ saturation was 64.77±13.33 %. DNA damage parameters such as tail length (24.02±11.34 vs. 16.88±3.55 μm, p=0.0001), tail moment (1.93±2.36 vs. 0.87±1.03 μm, p=0.013), tail migration (10.3±12.24 vs. 3.62±2.75, p=0.03) were significantly higher in

patients with PH.

 

Conslusion: These results suggest that patients with PH could have increased DNA damage before DNA repair mechanisms are at play. DNA damage could be contributing to the pathophysiology and may represent a novel pharmacological target in PH.

Keywords

• pulmonary hypertension,DNA damage

References

1. 1- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-223.
2. 2- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-2294. https://dx.doi.org/10.1161/CIRCULATIONAHA.109.192230
3. 3- Kishimoto Y, Kato T, Ito M, et al. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects. J Thorac Cardiovasc Surg 2015;150:645-654. https://dx.doi.org/10.1016/j.jtcvs.2015.05.052
4. 4- Cool C, Kennedy D, Voelkel N, Tuder R. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997,28:434-442.
5. 5- Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol 2015;31:407-415. https://dx.doi.org/10.1016/j.cjca.2014.10.023
6. 6- Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537. https://dx.doi.org/10.1093/eurheartj/ehp297
7. 7- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-1619. https://dx.doi.org/10.1016/j.jacc.2009.01.004
8. 8- Meloche J, Pflieger A, Vaillancourt M, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014;129:786-797. https://dx.doi.org/10.1161/CIRCULATIONAHA.113.006167

9. 9- Federici C, Drake KM, Rigelsky CM, et al. Increased mutagen sensitivity and dna damage in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:219-228. https://dx.doi.org/10.1164/rccm.201411-2128OC
10. 10- Nandhakumar S, Parasuraman S, Shanmugam MM, Rao KR, Chand P, Bhat BV. Evaluation of DNA damage using single-cell gel electrophoresis (Comet Assay). J Pharmacol Pharmacother 2011;2:107-111. https://dx.doi.org/10.4103/0976-500X.81903
11. 11- Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. https://dx.doi.org/10.1093/eurheartj/ehv317
12. 12- Dikilitaş M, Koçyiğit A. Canlılarda “tek hücre jel elektroforez” yöntemi ile DNA hasar analizi (teknik not): COMET analiz yöntemi. Harran Tarım ve Gıda Bilimleri Dergisi 2010;14,77-89.
13. 13- Davidson CJ, Bonow RO. Cardiac Catheterization. In: Mann DL, Zipes DP, Libby P, et al, ed. Braunwald’s Heart Disease. Philadelphia, PA: Elsevier; 2015;378.
14. 14- Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014;115:165-175. https://dx.doi.org/10.1161/CIRCRESAHA.113.301141
15. 15- Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001;38:581-587.16- Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-691. https://dx.doi.org/10.1161/01.RES.0000243584.45145.3f
16. 17- Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol 2018;104:9-13. https://dx.doi.org/10.1016/j.biocel.2018.08.015
17. 18- Chen PI, Cao A, Miyagawa K, et al. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight 2017;2:e90427. https://dx.doi.org/10.1172/jci.insight.90427
18. 19- Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-192. https://dx.doi.org/10.1038/nrc2344
19. 20- Ranchoux B, Meloche J, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. Int J Mol Sci 2016;17(6). pii: E990. https://dx.doi.org/10.3390/ijms17060990
20. 21- Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D; Darnell J. DNA damage and repair and their role in carcinogenesis. In: Molecular Cell Biology; WH. Freeman: New York, NY, USA, 2000.
21. 22- Diebold I, Hennigs JK, Miyagawa K, et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. Cell Metab 2015;21:596-608. https://dx.doi.org/10.1016/j.cmet.2015.03.010
22. 23- Li M, Vattulainen S, Aho J, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014;50:1118-1128. https://dx.doi.org/10.1165/rcmb.2013-0349OC
23. 24- Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. Turk Kardiyol Dern Ars 2014;42:17-28.
24. 25- Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013;62:D4-12. https://dx.doi.org/10.1016/j.jacc.2013.10.025
25. 26- de Jesus Perez VA, Yuan K, Lyuksyutova MA, et al. Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189:1260-1272. https://dx.doi.org/10.1164/rccm.201310-1749OC
26. 27- Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769. https://dx.doi.org/10.1164/rccm.200301-147OC
27. 28- Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347. https://dx.doi.org/10.1073/pnas.0605080104
28. 29- Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014;19:558-573. https://dx.doi.org/10.1016/j.cmet.2014.01.004
29. 30- Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW. DNA repair, genome stability, and aging. Cell 2005;120:497-512. https://dx.doi.org/10.1016/j.cell.2005.01.028
30. 31- Ou HL, Schumacher B. DNA damage responses and p53 in the aging process. Blood 2018;131:488-495. https://dx.doi.org/10.1182/blood-2017-07-746396